ArticleCureus2025
Reducing Contrast-Induced Nephropathy Risk in a Murine Model: Role of Avanafil and Vardenafil in Modulating Oxidant/Antioxidant Balance.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionContrast-induced nephropathy (CIN) is a major clinical problem, particularly under conditions of preexisting renal insufficiency and comorbidities. The present study evaluates the potential of phosphodiesterase type 5 inhibitors (PDE5is), avanafil (AVA), and vardenafil (VAR) to prevent CIN by modulating oxidative stress in a murine model.
methodsTwo sets of 25 male Wistar rats were allocated into five groups: control, CIN, N-acetylcysteine (NAC), VAR, and AVA. Indomethacin, L-NG-Nitro arginine methyl ester (L-NAME), and iopromide were used to induce CIN. Oxidative stress markers were evaluated, i.e., total antioxidant capacity (TAC), protein carbonyl (PROTC), thiobarbituric acid reactive substances (TBARS), glutathione (GSH), and catalase (CAT) activity.
resultsIn comparison with the control group, TAC, GSH, and CAT activity were reduced, while TBARS and PROTC levels were elevated in the CIN group. Variations in treatment by VAR, AVA, and NAC induced a notable rise in TAC and blood levels of GSH while lowering TBARS in tissue.
conclusionThe treatment groups with VAR, AVA, and NAC were noted with higher values of TAC, CAT, and GSH, while lower values of TBARS and PROTC indicated a protective effect against oxidative injury. The findings indicate that VAR and AVA effectively control the oxidant/antioxidant status, preventing oxidative stress and the incidence of CIN. Further research would be required to replicate these findings and identify the therapeutic potential of VAR and AVA in clinical conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.